Table 2 Comparison of demographic characteristics and disease activity of patients interviewed in Brazil and France
Brazil (N = 15) | France (N = 13) | |
|---|---|---|
Age (in years), Mean ± SD, range | 51 ± 11, 28–70 | 54 ± 17, 19–81 |
Female sex N (%) | 8 (53.3) | 6 (46.1) |
Mean PsA duration since diagnosis (in years) ± SD, range | 11.4 ± 10.0, 10 months to 33 years | 9.5 ± 6.7, 3 months to 20 years |
Mean PsA duration since beginning of symptoms (in years) ± SD, range | 16.5 ± 12.5, 8 months to 47 years | 14.4 ± 8.4, 1 to 29 years |
Educational level: patients with higher education (university level) N (%) | 0 (0.0) | 5 (38.5) |
Currently exerting professional activity N (%) | 7 (46.6) | 4 (30.8) |
Current or previous use of biological therapy N (%) | 5 (33.3) | 3 (23.0) |
Current BSA involved by psoriasis > 10% N (%) | 3 (20.0) | 0 (0.0) |
Patients with joint deformities N (%) | 8 (53.3) | 4 (30.7) |
Patient global VAS (0-100 mm) Mean ± SD, range | 54 ± 27, 7–92 | 40 ± 26, 0–86 |
Patient skin VAS (0-100 mm) Mean ± SD, range | 34 ± 26, 0–84 | 16 ± 17, 0–58 |
Patient pain VAS (0-100 mm) Mean ± SD, range | 55 ± 27, 3–82 | 37 ± 25, 0–87 |
Disability measures by HAQ | ||
Mild (HAQ 0–1) N (%) | 4 (26.7) | 10 (76.9) |
Moderate (HAQ > 1–2) N (%) | 7 (46.4) | 3 (23.0) |
Severe (HAQ > 2–3) N (%) | 4 (26.7) | 0 (0.0) |